HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pandemic-Driven Trends Show Strong Immunity Supplement Future, Elderberry A Current 'Darling'

Executive Summary

VMS, homeopathic and other natural producs firms couldn't plan for spike in demand from coronavirus 2019, but the pandemic provides information to continue riding heightened consumer interest to higher ongoing sales, researchers said in recent Council for Responsible Nutrition webinar.

You may also be interested in...



History With Emphasis On Stress Relief A Strength For New Chapter During Pandemic

“The growing trends in stress mean more customers will be looking for stress supportive products made from quality ingredients and based on clinical studies, which is exactly what New Chapter delivers,” says Charlotte Traas, the herbal supplement firm’s sales, education and content director.

Sabinsa’s Curcumin Complex Reduces Inflammation In Traumatic Brain Injury Patients

Iranian researchers found using 500 mg curcumin complex daily for seven days reduced levels of leptin, which can promote inflammatory response, in patients with traumatic brain injury. In study published in Phytotherapy Research, 28 subjects had an overall 47.1% reduction in leptin.

No Enforcement Immunity For Testimonials On Immunity Or Claims With 'Alert: No COVID-19 Cure'

Elderberry syrup marketer Provezza Health targeted review of claims consumers may link to COVID-19 prevention or treatment due to testimonials not dispelled by the firm. FDA and FTC warn CBD firm to discontinue claims noting immunity-boosting is the “best defense” against COVID-19.

Related Content

Topics

UsernamePublicRestriction

Register

LL1131561

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel